Molecular Docking and Interaction of Coumarin Derivatives as Inhibitors of Growth Factor Receptors

Authors

  • SAMEER SHARMA Indian Academy Degree College - Autonomous

Keywords:

Molecular docking, vascular endothelial growth factor receptor, Human epidermal growth factor receptor, coumarin, cancer, ADMET analysis, Phytocompounds, tyrosine kinases pathway

Abstract

Objective: Cancer is the largest cause of mortality in the globe, accounting for over 10 million deaths in 2020, or roughly one in every six. Because growth factor receptors are involved in the pathophysiology of the disease in several ways, human epidermal growth factors (HER-2 and HER-3) and vascular endothelial growth factor receptors (VEGFR-2 and VEGFR-3) might be as considered therapeutic targets. coumarins and derivatives were chosen for this study to investigate their pharmacological characteristics and therapeutic effect against the targeted proteins implicated in the pathogenesis of different cancers.

Methods:  In this work, 50 coumarins and their derivatives were chosen to assess their binding affinity with the targeted proteins (HER-2, HER-3, VEGFR-2, and VEGFR-3). PyRx, a virtual tool, was utilized to perform molecular docking. The investigation was carried out computationally, with data and molecular structures of the phytocompounds and proteins derived from Indian medicinal plants, phytochemistry, and therapeutics, as well as PubChem. The protein structure was validated using a variety of tools, including PDBsum generate and BIOVIA discovery studio software. The pharmacological assessment of the ligands was carried out using ADMET filters.

Result: According to the results of molecular docking, the ligands Glycycoumarin, Mutisifurocoumarin, Thunberginol A, Pervilleanine, Licocoumarin A, and Murrayacoumarin C had the lowest binding affinity towards the four targeted proteins.

Conclusion: Since these compounds are effective against the growth factor receptors implicated in cancer pathogenesis, they could be a suitable candidate for cancer management and suppression. However, in vitro research is still required to support these findings.

References

Ugai T, Sasamoto N, Lee H-Y, Ando M, Song M, Tamimi RM, et al. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat Rev Clin Oncol [Internet]. 2022 [cited 2022 Nov 16];19(10):656–73. Available from: https://www.nature.com/articles/s41571-022-00672-8

Fidler MM, Gupta S, Soerjomataram I, Ferlay J, Steliarova-Foucher E, Bray F. Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study. Lancet Oncol [Internet]. 2017;18(12):1579–89. Available from: http://dx.doi.org/10.1016/S1470-2045(17)30677-0

Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev [Internet]. 2015;34(1):157–64. Available from: http://dx.doi.org/10.1007/s10555-015-9552-6

Loibl S, Gianni L. HER2-positive breast cancer. Lancet [Internet]. 2017;389(10087):2415–29. Available from: http://dx.doi.org/10.1016/S0140-6736(16)32417-5

Vranić S, Bešlija S, Gatalica Z. Targeting HER2 expression in cancer: New drugs and new indications. Bosn J Basic Med Sci [Internet]. 2021;21(1):1–4. Available from: http://dx.doi.org/10.17305/bjbms.2020.4908

Wang S-L, Zhong G-X, Wang X-W, Yu F-Q, Weng D-F, Wang X-X, et al. Prognostic significance of the expression of HER family members in primary osteosarcoma. Oncol Lett [Internet]. 2018;16(2):2185–94. Available from: http://dx.doi.org/10.3892/ol.2018.8931

Liu X, Liu S, Lyu H, Riker AI, Zhang Y, Liu B. Development of effective therapeutics targeting HER3 for cancer treatment. Biol Proced Online [Internet]. 2019;21(1):5. Available from: http://dx.doi.org/10.1186/s12575-019-0093-1

Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med [Internet]. 2013;273(2):114–27. Available from: http://dx.doi.org/10.1111/joim.12019

Klasa-Mazurkiewicz D, Jarząb M, Milczek T, Lipińska B, Emerich J. Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients. Pol J Pathol. 2011;62(1):31–40.

Su J-L, Yen C-J, Chen P-S, Chuang S-E, Hong C-C, Kuo I-H, et al. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer [Internet]. 2007;96(4):541–5. Available from: http://dx.doi.org/10.1038/sj.bjc.6603487

Tomeh MA, Hadianamrei R, Zhao X. A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci [Internet]. 2019;20(5):1033. Available from: http://dx.doi.org/10.3390/ijms20051033

Nakamura K, Shimura N, Otabe Y, Hirai-Morita A, Nakamura Y, Ono N, et al. KNApSAcK-3D: a three-dimensional structure database of plant metabolites. Plant Cell Physiol [Internet]. 2013;54(2):e4. Available from: http://dx.doi.org/10.1093/pcp/pcs186

Sayers EW, Beck J, Bolton EE, Bourexis D, Brister JR, Canese K, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res [Internet]. 2021;49(D1):D10–7. Available from: http://dx.doi.org/10.1093/nar/gkaa892

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res [Internet]. 2000;28(1):235–42. Available from: http://dx.doi.org/10.1093/nar/28.1.235

Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res [Internet]. 2018;46(W1):W296–303. Available from: http://dx.doi.org/10.1093/nar/gky427

Panikar S, Shoba G, Arun M, Sahayarayan JJ, Usha Raja Nanthini A, Chinnathambi A, et al. Essential oils as an effective alternative for the treatment of COVID-19: Molecular interaction analysis of protease (Mpro) with pharmacokinetics and toxicological properties. J Infect Public Health [Internet]. 2021;14(5):601–10. Available from: http://dx.doi.org/10.1016/j.jiph.2020.12.037

Tam B, Sinha S, Wang SM. Combining Ramachandran plot and molecular dynamics simulation for structural-based variant classification: Using TP53 variants as model. Comput Struct Biotechnol J [Internet]. 2020;18:4033–9. Available from: http://dx.doi.org/10.1016/j.csbj.2020.11.041

Laskowski RA. PDBsum: summaries and analyses of PDB structures. Nucleic Acids Res [Internet]. 2001;29(1):221–2. Available from: http://dx.doi.org/10.1093/nar/29.1.221

Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol [Internet]. 2015;1263:243–50. Available from: http://dx.doi.org/10.1007/978-1-4939-2269-7_19

Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res [Internet]. 2021;49(W1):W5–14. Available from: http://dx.doi.org/10.1093/nar/gkab255

Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer [Internet]. 2004;46(1):11–9. Available from: https://www.sciencedirect.com/science/article/pii/S0169500204001412

Roy PS, Saikia BJ. Cancer and cure: A critical analysis. Indian J Cancer [Internet]. 2016 [cited 2022 Nov 16];53(3):441–2. Available from: https://www.indianjcancer.com/article.asp?issn=0019-509X;year=2016;volume=53;issue=3;spage=441;epage=442;aulast=Roy

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature [Internet]. 2018;554(7691):189–94. Available from: http://dx.doi.org/10.1038/nature25475

Yonesaka K. HER2-/HER3-targeting antibody-drug conjugates for treating lung and colorectal cancers resistant to EGFR inhibitors. Cancers (Basel) [Internet]. 2021;13(5):1047. Available from: http://dx.doi.org/10.3390/cancers13051047

Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. Genes Cancer [Internet]. 2011;2(12):1097–105. Available from: http://dx.doi.org/10.1177/1947601911423031

Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer [Internet]. 2013;13(12):871–82. Available from: http://dx.doi.org/10.1038/nrc3627

Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer [Internet]. 2011;10(1):12. Available from: http://dx.doi.org/10.1186/1476-4598-10-12

Muninggar L, Widjiati W, Yuliati I, Askandar B, Hartono P. Effects of curcumin on vascular endothelial growth factor expression on Rattus norvegicus cervical cancer xenograft model. Indonesian Journal of Cancer [Internet]. 2019 [cited 2022 Nov 16];12(3):95. Available from: https://media.neliti.com/media/publications/274566-effects-of-curcumin-on-vascular-endothel-3df4248f.pdf

He S-D, Yang X-T, Yan C-C, Jiang Z, Yu S-H, Zhou Y-Y, et al. Promising compounds from Murraya exotica for cancer metastasis chemoprevention. Integr Cancer Ther [Internet]. 2017;16(4):556–62. Available from: http://dx.doi.org/10.1177/1534735416678981

Song X, Yin S, Zhang E, Fan L, Ye M, Zhang Y, et al. Glycycoumarin exerts anti-liver cancer activity by directly targeting T-LAK cell-originated protein kinase. Oncotarget [Internet]. 2016;7(40):65732–43. Available from: http://dx.doi.org/10.18632/oncotarget.11610

Takeuchi K, Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull [Internet]. 2011;34(12):1774–80. Available from: https://www.jstage.jst.go.jp/article/bpb/34/12/34_12_1774/_article/-char/ja/

Published

16-01-2023

How to Cite

SHARMA, S. (2023). Molecular Docking and Interaction of Coumarin Derivatives as Inhibitors of Growth Factor Receptors. Innovare Journal of Medical Sciences, 11(2). Retrieved from https://innovareacademics.in/journals/index.php/ijms/article/view/47145

Issue

Section

Original Article(s)